Markets:

Overview

News

Currencies

International

Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

73.02 -1.47 (-1.97%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites

December 11, 2023

TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of BID or TID dosing, and was well tolerated

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

November 10, 2023

Shares of Wynn Resorts, Limited (NASDAQ: WYNN) fell sharply on Friday after the company reported third-quarter financial results.

Via Benzinga

Recap: Tarsus Pharmaceuticals Q3 Earnings ↗

November 09, 2023

Via Benzinga

HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know ↗

November 10, 2023

Via Benzinga

Big Stocks Moving Higher On Friday: Synaptics Reports Q1 Beat; Joins Lyft, Hologic, Blink Charging ↗

November 10, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Friday. Shares of Synaptics Incorporated (NASDAQ: SYNA) rose sharply on Friday after the company reported better-than-expected...

Via Benzinga

Topics Stocks

Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Making Surprising Moves in Friday Session

November 10, 2023

Via Investor Brand Network

Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements

November 09, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Earnings Preview: Tarsus Pharmaceuticals ↗

November 08, 2023

Via Benzinga

Expert Ratings for Tarsus Pharmaceuticals ↗

September 11, 2023

Via Benzinga

What 6 Analyst Ratings Have To Say About Tarsus Pharmaceuticals ↗

August 14, 2023

Via Benzinga

HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know ↗

July 26, 2023

Via Benzinga

Earnings Scheduled For November 9, 2023 ↗

November 09, 2023

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.

Via Benzinga

Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

November 01, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

September 06, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus to Present at Upcoming Investor Conferences

August 30, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

August 24, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements

August 10, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock

August 01, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 01, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 31, 2023

Via Benzinga

Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock

July 31, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Pharma Shares Under Pressure: Analyst Says Concerns Over Adverse Event Profile Overblown ↗

July 25, 2023

The FDA approved Tarsus Pharmaceuticals Inc's (NASDAQ: TARS) Xdemvy (lotilaner ophthalmic solution) 0.25% for

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 25, 2023

Via Benzinga

Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 25, 2023

Gainers Aurora Acquisition Corp. (NASDAQ: AURC) shares jumped 192% to $30.54.

Via Benzinga

FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis

July 25, 2023

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Why Shares of Tarsus Pharmaceuticals Are Up Thursday ↗

July 20, 2023

The company's lead therapy is getting close to the finish line of FDA approval.

Via The Motley Fool

Why Infosys Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

July 20, 2023

Gainers PainReform Ltd. (NASDAQ: PRFX) jumped 45.5% to $10.34 after declining 8% on Wednesday. PaiReform recently regained compliance with Nasdaq continued listing requirements.

Via Benzinga

Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Climbs to New 52-Week High

July 20, 2023

Via Investor Brand Network

Johnson & Johnson, Zions Bancorporation, Heritage-Crystal Clean And Other Big Stocks Moving Higher On Thursday ↗

July 20, 2023

U.S. stocks traded mixed, with the Dow Jones gaining over 200 points on Thursday. Here are some big stocks recording gains in today’s session. Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) shares rose...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 18, 2023 ↗

July 18, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.